Medicines360

Healthcare for each woman. Access for all women.
In the News
A Promising New Birth Control Device Is Specifically Meant To Help Low-Income Women
Disrupting drug delivery: This exec believes a nonprofit model can deliver affordable drugs to women around the world
With FDA Nod, Nonprofit Drug Firm Launches New IUD - And New Model
The above trademarks and service marks are the property of their respective owners. Their use herein is for informational purposes only and does not suggest any affiliation, endorsement, or sponsorship of Medicines360 or its goods and services.
 
Press Releases
Medicines360 and Allergan Announce Partnership with Health Centers to Help Address Unintended Pregancies in Areas Impacted by Zika
15
FEB
2017
Medicines360, a nonprofit women's health pharmaceutical company with a mission of expanding access to quality medicines, and Allergan plc (NYSE:AGN), a leading global pharmaceutical company, today announced a partnership with 340B-eligible health centers and other safety net providers in Puerto Rico and Florida, both areas where there is local transmission of the Zika virus, to make available their hormonal contraceptive, LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg. LILETTA is an IUS, intrauterine system (otherwise known as an intrauterine device or IUD), that is approved for the prevention of pregnancy for up to three years.
FDA Accepts for Filing Supplemental New Drug Application (sNDA) for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg
03
JAN
2017
Allergan plc, (NYSE: AGN) a leading global pharmaceutical company, and Medicines360, a nonprofit global women's health pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the company’s supplemental New Drug Application (sNDA) to potentially extend the duration of use for the prevention of pregnancy from up to three years to up to four years for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg.
Medicines360 and Allergan Announce Study Publication Evaluating Pelvic Infection Risk Following Same-Day Sexually Transmitted Infection Testing and LILETTA (levonorgestrel-releasing intrauterine system) 52 mg Placement
15
NOV
2016
Medicines360, a nonprofit global women's health pharmaceutical company, and Allergan, plc (NYSE: AGN), a leading global pharmaceutical company, today announced the publication of, “A prospective assessment of pelvic infection risk following same-day sexually transmitted infection testing and levonorgestrel intrauterine system placement” in the November, 2016 medical journal, American Journal of Obstetrics & Gynecology.
Medicines360 and Population Services International Announce New Partnership to Expand Access to Hormonal IUDs to Women in Africa
28
SEP
2016
Medicines360, a global nonprofit pharmaceutical company, and Population Services International (PSI), a leading global health organization working in reproductive health, announced today an agreement to expand access to Medicines360's hormonal intrauterine device (IUD) (levonorgestrel-releasing intrauterine system) 52 mg.
Allergan and Medicines360 Announce Launch of New LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg Single-Handed Inserter
14
SEP
2016
Allergan plc, (NYSE: AGN) a leading global pharmaceutical company, and Medicines360, a nonprofit global women's health pharmaceutical company, today announced the launch of the new LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg IUD single-handed inserter (intrauterine device), for use by women to prevent pregnancy for up to three years.
Medicines360 and Allergan announce publication of levonorgestrel release rates over five years with the LILETTA® 52 mg intrauterine system in Contraception
7
SEP
2016
Medicines360, a nonprofit global women's health pharmaceutical company, and Allergan, plc (NYSE: AGN), a leading global pharmaceutical company, today announced the publication of five-year levonorgestrel release rates for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg in the September 2016 issue of the medical journal Contraception.
Allergan and Medicines360 Announce Donation of Intrauterine Devices (IUD) to the Centers for Disease Control (CDC) Foundation to Help Address Microcephaly Impact from Zika Virus in Puerto Rico
31
MAY
2016
Allergan plc, a leading global pharmaceutical company, and Medicines360, a nonprofit women's health pharmaceutical company with a mission of expanding access to quality medicines, today announced that they will donate 10,000 units of their hormonal IUD, LILETTA®.
Medicines360 Announces New Partnership With Marie Stopes International To Expand Access To Its Hormonal IUD To Women In Kenya, East Africa
07
DEC
2015
Medicines360, a global nonprofit pharmaceutical company, today announced an agreement with Marie Stopes International (MSI), a global nonprofit family planning organization, to expand access to Medicines360's hormonal intrauterine device, LNG IUS (levonorgestrel-releasing intrauterine system, 52mg), bringing further contraceptive options to the women of Kenya.
Medicines360 Names Jessica Grossman as CEO
08
JUL
2015
Medicines360, a global nonprofit women’s health pharmaceutical company with a mission of expanding access to quality medicines, today announced that the company has appointed Jessica Grossman, M.D., as its Chief Executive Officer, effective immediately. Dr. Grossman has been chair of the Board of Directors of Alliance Partners360, Medicines360’s for-profit subsidiary, since 2014 and a director of Medicines360 since 2011.
Actavis and Medicines360 Announce Publication of ACCESS IUS Efficacy and Safety Study of LILETTA™ (Levonorgestrel-Releasing Intrauterine System) 52 mg in Contraception
28
APR
2015
The study found that LILETTA™ (levonorgestrel-releasing intrauterine system) 52 mg, is 99.45% effective for the prevention of pregnancy for up to three years of use in women aged 16-35 regardless of race, parity (previous births), or body mass index (BMI). The ACCESS IUS trial is still ongoing and will evaluate the efficacy and safety of LILETTA for up to seven years of use.
Actavis and Medicines360 Announce U.S. Availability of LILETTA™ (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Three Years
13
APR
2015
Actavis plc (NYSE: ACT), a leading global pharmaceutical company and leader in women’s health care, and Medicines360, a nonprofit women’s health pharmaceutical company, announced today that LILETTA™ (levonorgestrel-releasing intrauterine system) 52 mg is now available in the U.S. for use by women to prevent pregnancy for up to three years.
Actavis and Medicines360 Announce FDA Approval of LILETTA™ (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Three Years
27
FEB
2015
Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, and Medicines360, a nonprofit women’s health pharmaceutical company, today announced the approval of LILETTA™ (levonorgestrel-releasing intrauterine system) by the U.S. Food and Drug Administration (FDA) for use by women to prevent pregnancy for up to three years. LILETTA is placed in the uterus by a healthcare professional and works by continuously releasing levonorgestrel, a progestin, to prevent pregnancy.
Medicines360 and Actavis Announce FDA Acceptance for Filing of NDA for Levosert™ IUD
21
JUL
2014
Medicines360, a non-profit women’s health pharmaceutical company, and Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Medicines360’s New Drug Application (NDA) for Levosert™ (levonorgestrel), a hormonal intrauterine contraceptive (IUC) for use by women to prevent pregnancy.
Actavis and Medicines360 Announce Partnership to Advance Women’s Access to Affordable IUDs
11
JUN
2013
Medicines360, a non-profit pharmaceutical company, and Actavis, Inc., a leading global specialty pharmaceutical company, today announced a historic partnership to support Medicines360’s mission to reduce cost as a barrier to accessing women’s birth control. The Medicines360 and Actavis partnership will make the IUD available in the U.S. commercially and at a very low price in U.S.public sector clinics. As part of this agreement, Actavis has licensed the U.S. commercial rights for the Medicines360 LNG20 Intrauterine Device (IUD).
Collaboration to Develop State-of-the-Art Levonorgestrel Releasing Intrauterine Device (LNG IUD) As Highly Effective Long-acting Reversible Contraceptive
18
DEC
2009
Medicines360, the US-based non-profit that addresses unmet medical needs of women and children by developing innovative, affordable and sustainable medical solutions, today announced a strategic partnership with European women’s health pharmaceutical company Uteron Pharma Operations (UPO), based in Liege Belgium, to develop a long-acting LNG IUD. As part of the collaborative agreement, Uteron is responsible for the design and manufacture of the product, and Medicines360 is responsible for Phase III clinical development.